Literature DB >> 33214690

PD1 inhibitor in combination with 5-azacytidine and low-dose DLI for the successful treatment of AML patients who relapsed after transplantation.

Chong-Sheng Qian1,2, Xiao Ma1,2, Jin Wang3, Ting-Jing Wang1,2, Lian Bai4, Hai-Xia Zhou1,2, Ming-Zhu Xu1,2, Ai-Ning Sun1,2, De-Pei Wu1,2, Song-Bai Liu5, Sheng-Li Xue6,7.   

Abstract

Entities:  

Year:  2020        PMID： 33214690     DOI： 10.1038/s41409-020-01130-8

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  9 in total

1.  Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study.

Authors:  Padmanee Sharma; Hagop Kantarjian; Naval Daver; Guillermo Garcia-Manero; Sreyashi Basu; Prajwal C Boddu; Mansour Alfayez; Jorge E Cortes; Marina Konopleva; Farhad Ravandi-Kashani; Elias Jabbour; Tapan Kadia; Graciela M Nogueras-Gonzalez; Jing Ning; Naveen Pemmaraju; Courtney D DiNardo; Michael Andreeff; Sherry A Pierce; Tauna Gordon; Steven M Kornblau; Wilmer Flores; Zainab Alhamal; Carlos Bueso-Ramos; Jeffrey L Jorgensen; Keyur P Patel; Jorge Blando; James P Allison
Journal:  Cancer Discov       Date:  2018-11-08       Impact factor: 39.397

2.  A multicentre UK study of GVHD following DLI: rates of GVHD are high but mortality from GVHD is infrequent.

Authors:  J J Scarisbrick; F L Dignan; S Tulpule; E D Gupta; S Kolade; B Shaw; F Evison; G Shah; E Tholouli; G Mufti; A Pagliuca; R Malladi; K Raj
Journal:  Bone Marrow Transplant       Date:  2014-10-13       Impact factor: 5.483

3.  Ipilimumab for Patients with Relapse after Allogeneic Transplantation.

Authors:  Matthew S Davids; Haesook T Kim; Pavan Bachireddy; Caitlin Costello; Rebecca Liguori; Alexandra Savell; Alexander P Lukez; David Avigan; Yi-Bin Chen; Peter McSweeney; Nicole R LeBoeuf; Michael S Rooney; Michaela Bowden; Chensheng W Zhou; Scott R Granter; Jason L Hornick; Scott J Rodig; Masahiro Hirakawa; Mariano Severgnini; F Stephen Hodi; Catherine J Wu; Vincent T Ho; Corey Cutler; John Koreth; Edwin P Alyea; Joseph H Antin; Philippe Armand; Howard Streicher; Edward D Ball; Jerome Ritz; Asad Bashey; Robert J Soiffer
Journal:  N Engl J Med       Date:  2016-07-14       Impact factor: 91.245

Review 4.  Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation.

Authors:  Thomas Schroeder; Christina Rautenberg; Rainer Haas; Ulrich Germing; Guido Kobbe
Journal:  Int J Hematol       Date:  2017-11-15       Impact factor: 2.490

Review 5.  Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited.

Authors:  Abhinav Deol; Lawrence G Lum
Journal:  Cancer Treat Rev       Date:  2010-04-09       Impact factor: 12.111

6.  Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma.

Authors:  Jing Nie; Chunmeng Wang; Yang Liu; Qingming Yang; Qian Mei; Liang Dong; Xiang Li; Jiejie Liu; Wenjing Ku; Yan Zhang; Meixia Chen; Xiaojing An; Lu Shi; Malcolm V Brock; Jie Bai; Weidong Han
Journal:  J Clin Oncol       Date:  2019-04-30       Impact factor: 44.544

Review 7.  Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic Targets.

Authors:  Maximilian Stahl; Aaron D Goldberg
Journal:  Curr Oncol Rep       Date:  2019-03-23       Impact factor: 5.075

8.  Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies.

Authors:  Raanan Berger; Rinat Rotem-Yehudar; Gideon Slama; Shimon Landes; Abraham Kneller; Merav Leiba; Maya Koren-Michowitz; Avichai Shimoni; Arnon Nagler
Journal:  Clin Cancer Res       Date:  2008-05-15       Impact factor: 12.531

Review 9.  Checkpoint inhibitors and acute myelogenous leukemia: promises and challenges.

Authors:  Mansour Alfayez; Gautam Borthakur
Journal:  Expert Rev Hematol       Date:  2018-05       Impact factor: 2.929
  9 in total
  2 in total

Review 1.  Epi-immunotherapy for cancers: rationales of epi-drugs in combination with immunotherapy and advances in clinical trials.

Authors:  Yang Xu; Ping Li; Yang Liu; Dijia Xin; Wen Lei; Aibin Liang; Weidong Han; Wenbin Qian
Journal:  Cancer Commun (Lond)       Date:  2022-06-01

Review 2.  Hypomethylating Agent-Based Combination Therapies to Treat Post-Hematopoietic Stem Cell Transplant Relapse of Acute Myeloid Leukemia.

Authors:  Giulia Ciotti; Giovanni Marconi; Giovanni Martinelli
Journal:  Front Oncol       Date:  2022-01-06       Impact factor: 6.244
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.